SABS
SAB Biotherapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | |
| – | – | 2.7% | 13.8% | 167.3% | 362.4% | – | |
| 100.0% | 100.0% | 97.3% | 86.2% | -67.3% | -262.4% | – | |
| 233.0% | 50.5% | 93.9% | 152.4% | 737.6% | 2,281.1% | – | |
| 119.0% | 12.3% | 28.1% | 68.5% | 1,062.9% | 1,057.2% | – | |
| 352.0% | 62.8% | 119.3% | 207.2% | 1,633.3% | 2,982.5% | – | |
| -252.0% | 37.2% | -22.0% | -121.0% | -1,700.5% | -3,244.9% | – | |
| 12.4% | 0.8% | 0.5% | 1.3% | 14.1% | 24.1% | – | |
| -261.1% | 36.4% | -28.2% | -78.3% | -1,884.5% | -2,579.0% | – | |
| 12.5% | 0.9% | 0.5% | 0.1% | 0.0% | – | – | |
| -261.1% | 36.4% | -28.2% | -78.4% | -1,884.5% | -2,579.0% | – | |
| -239.2% | 38.3% | -25.0% | -63.3% | -1,703.1% | -2,192.5% | – |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.